How to best define target populations of medicines in view of their coverage by the national health insurance scheme?
Therapie. 2010 Jul-Aug;65(4):341-5, 335-9.
doi: 10.2515/therapie/2010034.
Epub 2010 Sep 21.
[Article in
English,
French]
Collaborators
-
participates of Round Table n° 5 Giens XXV:
Annick Alperovitch, Pascal Auquier, Marion Bamberger, Marie-Noëlle Banzet, Jean-Pierre Boissel, Thomas Borel, Catherine Denis, Antoine Flahault, Marie-Laurence Gourlay, Pascale Jolliet, Jean-Michel Joubert, Michel Lièvre, Patrick Maison, Arlette Meyer, Nicholas Moore, Laure Prestat-Sledziewski, Frank Rouby, Nathalie Schmidely, Anne Solesse, Bernard Teisseire, Daniel Vasmant, Didier Veron, Patrick Villani, Laura Zanetti, Mahmoud Zureik, Myriam Zylberman
Affiliation
- 1 Service Evaluation Economique et de Santé Publique, Haute Autorité de Santé, Saint-Denis La Plaine Cedex, France.
Abstract
The target population of a medicine may include different populations that may partially overlap including the population that has been evaluated in the clinical trials, the population for which the medicine provides an actual benefit (SMR), that for which the drug provides an improvement of the actual benefit (ASMR), etc. The definition of the target population in both qualitative and quantitative terms has key public health and economic implications. Recommendations are made to shed light on the definitions, to clarify the requests of the public decision makers and to improve the methods and the sources allowing the quantification of target populations.
© 2010 Société Française de Pharmacologie et de Thérapeutique.
MeSH terms
-
Drug Therapy / standards*
-
France
-
Guidelines as Topic
-
Health Services Needs and Demand
-
Humans
-
National Health Programs / standards*
-
Population